Real-World Outcomes of Talquetamab In relapsed/refractory Multiple Myeloma and Renal Impairment

Key Points

• Positive outcomes were observed in patients with relapsed/refractory multiple myeloma and renal impairment.
• Overall response rates reached up to 50% among treated individuals with renal issues.
• Analysis of patient records indicated significant efficacy of talquetamab over standard treatments.
• The findings highlight the need for greater awareness of treatment options for patients with both conditions.